Home / Meet The Team

PhrmaSec is founded by a team of young enthusiastic researchers along with excellent guidance of experienced scientists and businessmen. Although PhrmaSec is at the early stage of development, we are proud to have experienced research-management team, collaborators and visionary advisors on board. Our multi-disciplinary team has expertise in drug development & research, endocrinology, biochemistry, business development, financial and legal aspects. It makes PhrmaSec a proficient company in the Hong Kong’s biotechnology industry.


Professor Billy Chow Kwok Chong, (Ph.D.); Founder, Chief Scientific Advisor
Dr. Chow is a Chair Professor of Endocrinology at The University of Hong Kong and currently serving as Associate Dean of the Faculty of Sciences. He is a proud recipient of the International Grace Pickford Award (2005), the International Akira Arimura Young Investigator Award (2007) as well as The Outstanding Researcher Award (2005) and Research Output Prize (2010) by The University of Hong Kong. Prof. Chow has received numerous invitations to give plenary and State-of-the-Art lectures in international congresses and is the senior editor for several peer-reviewed journals. Prof. Chow is renowned for his research in molecular endocrinology, with special focus on G-protein coupled receptors and the first hormone identified, secretin, and discovery of novel bioactive peptides. The latest breakthrough from Prof. Chow’s laboratory is that his group has substantiated secretin as a brain and pituitary neuropeptideregulating water salt homeostasis in our body.

Dr. Kailash

Dr. Kailash Singh, (Ph.D.); CEO, Founder Director

Dr. Kailash Singh is an enthusiastic researcher with background in biomedical sciences, biotechnology and bioinformatics. Dr. Singh has a master degree in biotechnology. Prior to starting his Ph.D. studies at The University of Hong Kong, he had worked as a scientist in DobleHelix Pvt. Ltd. in New Delhi, India. With his expertise in in-silico drug design and structural biology, during his Ph.D. studies he has published 12 research articles in international journals. Also, Dr. Singh developed the novel small compound positive allosteric modulator for secretin receptor (i.e. KSD179019) (Patent pending). He will be responsible for overseeing the research projects in PhrmaSec and coordinating between different collaboration parties. Dr. Singh has a cross-disciplinary background which adds value to the whole team.

Professor Illana Gozes

Professor Illana Gozes, (Ph.D.); Scientific Advisor
Dr. Gozes is a Professor of Clinical Biochemistry, the Lily and Avraham Gildor Chair for the Investigation of Growth factors at Tel Aviv University, where she directs the Adams Super Center for Brain Studies. At the Sackler Faculty of Medicine, Prof. Gozes heads the Dr. Diana and Zelman Elton (Elbaum) Laboratory for Molecular Neuroendocrinology (including 14 staff members). Prof. Gozes has served as a member (or chair) of several faculty/university/national and international committees and is currently the Editor-in Chief of the Journal of Molecular Neuroscience. She serves as the President of the Israel Society for Neuroscience. Prof. Gozes co-founded and serves as the Chief Scientific Officer and Member of the Board of Directors at Allon Therapeutics Inc., the Canadian clinical – stage neuroprotection company (TSX:NPC), focused on developing drugs that impact the progression of neurodegenerative diseases.

Professor Victor May

Professor Victor May, (Ph.D.); Scientific Advisor
Dr. May is a Professor of Neurological Science at The University of Vermont, USA. Prof. May is a dedicated researcher of neurotransmitter, neuropeptide, and G-protein coupled receptor. Recently, his investigation has been dedicated to pituitary adenylate cyclase activating polypeptide. Prof. May has been doing pioneering work on pituitary adenylate cyclase activating polypeptide receptor’s structural understanding and is working on developing small compound agonist for this receptor.

Dr. Jerome Leprince,

Dr. Jerome Leprince, (Ph.D.); Scientific Advisor
Dr. Leprince is a researcher in INSERM institute, France and is also working as Project Manager on the peptide synthesis and functional screening facilities of PRIMACEN Cellular Imaging Platform.Dr. Leprince is currently the Chairman for subcommittee of the QRFP receptor of the IU-PHAR and was the Chairman of French Peptide. Dr. Leprince was the Chairman of 21st International Symposium on Regulatory Peptides, France, 2016. Also, Dr. Leprince was the organizer and Chairman of the symposium Cardiovascular Peptide Hormone GPCRs: New Insights into Ligand-Receptor Interactions and Implications for Drug Discovery. Dr. Leprince is a peptide chemist who has been studying the structure-activity relationships of neuropeptides for over 20 years with significant success in the design of stable and potent G protein-coupled receptor agonists and antagonists.

Dr. Kenneth Lai

Dr. Kenneth Lai, (Ph.D.); Business Development Advisor.
Dr. Lai is a serial entrepreneur who is the founder of several biotech companies. One of his companies was proudly selected as the top 20 startups in the world by CNBC in 2014 and was awarded a number of international and local recognitions such as; The Global Top 15 by Innovation Forum in 2016, French Tech Ticket winner in 2017 and Hong Kong Champion of IPIES Global 2018. He has extensive hands-on experience on startup operation and development strategy. He obtained his Ph.D. from The University of Hong Kong. Dr. Lai is the inventor of 2 international patents and published more than 10 publications in international journal articles as well as invited book chapters.

Dr. Ian Lam

Dr. Ian Lam, (Ph.D.); Technical Advisor
Dr. Lam received his Ph.D. degree in molecular endocrinology specializing in secretin from The University of Hong Kong. Dr. Lam also has an extensive experience in drug development in different areas, including oncology and neural degenerative diseases.

Mr. Bobby Chow

Mr. Bobby Chow (MBA); Financial Advisor
Mr. Chow is an experienced investment banker and has an extensive experience in corporate finance and merges and acquisitions. Mr. Chow covers various industries at different development stages from early stage, pre-IPO to post-IPO. Mr. Chow holds an MBA degree and a B.Sc. degree in Biotechnology from The University of Hong Kong. Mr. Chow is currently the Honorary Director of HK Bio-Med Innotech Association.

Collaborator Labs
Professor B.K.C Chow

Professor B.K.C Chow’s lab:
Prof. Chow is also the Chief scientific advisor and founder of this company. His lab has decades of experience in secretin related research and have published over a hundred of related research articles in international journals. His lab holds expertise in rodent handling and is equipped for conducting research relating to the pre-clinical studies for KSD171990.

Dr. Hani S. El-Nezam

Dr. Hani S. El-Nezam’s Lab:
Dr. Hani is a certified Toxicologist and is currently working as an Associate Professor in the School of Biological Sciences at The University of Hong Kong. His major research interest is in food toxicology and therefore his lab is equipped for the necessary toxicological testing. Dr. Hani is going to provide his insight for the acute, sub-acute and chronic toxicological studies of KSD179019. Our collaboration with Dr. Hani’s lab is through Prof. B.K.C Chow’s lab.

Professor. Zuo Zhong

Professor. Zuo Zhong, Joan’s lab:
Professor Joan Zuo is the Director of the School of Pharmacy at the Chinese University of Hong Kong. She holds a B. Sc. and a Ph.D. in Pharmaceutical Sciences and has had over 20 years’ experience in the biopharmaceutics and pharmacokinetics fields. Her lab hold expertise in pharmacodynamics and pharmacokinetic studies and hence is a valuable asset for the crucial preclinical studies for KSD179019.

Dr. Ng Wai-Lung, Billy

Dr. Ng Wai-Lung, Billy:
Professor Ng is Assistant Professor at the School of Pharmacy at Chinese University of Hong Kong. Professor Ng obtained his B.Sc. degree in Chemistry and Ph.D. in Organic Chemistry from the Chinese University of Hong Kong. During his graduate study, he was a Fulbright Scholar at Massachusetts Institute of Technology (MIT). From 2014 – 2016, he joined the University of Oxford as a Croucher Foundation Postdoctoral Fellow. He was then recruited to Harvard Medical School / Dana-Farber Cancer Institute as a research fellow from 2016 – 2019. Dr. Ng has research interests and background in chemical biology, drug discovery, and medicinal chemistry. The Ng lab uses chemical, biological, and bioinformatics tools to develop novel molecules for the treatment and diagnosis of various diseases, including cancers, diabetes, and neurodegenerative diseases.